Bispecific antibodies: molecules that enable novel therapeutic strategies
- PMID: 17496428
- DOI: 10.1159/000101046
Bispecific antibodies: molecules that enable novel therapeutic strategies
Abstract
Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials.
Copyright (c) 2007 S. Karger AG, Basel.
Comment in
-
Paul Ehrlich no end: antibodies as therapeutic molecules.Pathobiology. 2007;74(1):1-2. doi: 10.1159/000101045. Pathobiology. 2007. PMID: 17496427 No abstract available.
Similar articles
-
Bispecific antibodies for cancer therapy.Immunotherapy. 2009 Mar;1(2):211-22. doi: 10.2217/1750743X.1.2.211. Immunotherapy. 2009. PMID: 20635943 Review.
-
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.Curr Opin Mol Ther. 2008 Jun;10(3):273-84. Curr Opin Mol Ther. 2008. PMID: 18535935
-
Diabodies: molecular engineering and therapeutic applications.Drug News Perspect. 2009 Oct;22(8):453-8. Drug News Perspect. 2009. PMID: 20016854 Review.
-
Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1. Methods Enzymol. 2012. PMID: 22208980
-
Recombinant bispecific antibodies for cellular cancer immunotherapy.Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Curr Opin Mol Ther. 2007. PMID: 17694444 Review.
Cited by
-
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.MAbs. 2015;7(5):946-56. doi: 10.1080/19420862.2015.1062192. MAbs. 2015. PMID: 26083076 Free PMC article.
-
LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.J Biol Chem. 2012 Dec 21;287(52):43331-9. doi: 10.1074/jbc.M112.397869. Epub 2012 Nov 1. J Biol Chem. 2012. PMID: 23118228 Free PMC article.
-
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.AMB Express. 2016 Dec;6(1):32. doi: 10.1186/s13568-016-0201-4. Epub 2016 Apr 26. AMB Express. 2016. PMID: 27112931 Free PMC article.
-
Emerging antibody combinations in oncology.MAbs. 2011 Jul-Aug;3(4):338-51. doi: 10.4161/mabs.3.4.16615. Epub 2011 Jul 1. MAbs. 2011. PMID: 21697653 Free PMC article. Review.
-
Chemical generation of bispecific antibodies.Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13. Proc Natl Acad Sci U S A. 2010. PMID: 21149738 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources